膀胱移行细胞癌中Ki-67与p53及VEGF的表达及临床意义

费夏玮; 刘光香; 祝帅; 陈崯; 陈骏; 张士伟; 赵晓智; 刘铁石; 姚林方; 李笑弓; 郭宏骞

膀胱移行细胞癌中Ki-67与p53及VEGF的表达及临床意义

- 1. 南京大学医学院附属鼓楼医院泌尿外科(南京, 210008);
- 2. 南京大学医学院附属鼓楼医院病理科

详细信息

通讯作者: 李笑弓,E-mail:lxg6691@126.com

中图分类号: R737.14

收稿日期: 2013-04-26

Expression and clinical significance of Ki-67, p53 and VEGF in transitional cell carcinoma of the bladder

- 1. Department of Urology, Affiliated Drum Tower Hospital, Medical College of Nanjing University, Nanjing, 210008, China;
- 2. Department of Pathology, Affiliated Drum Tower Hospital, Medical College of Nanjing University

More Information

Corresponding author: LI Xiaogong, E-mail: lxg6691@126.com

Received Date: 26 April 2013

摘要

摘要: 目的：探讨膀胱移行细胞癌（TCCB）中Ki-67与p53、VEGF的表达与TCCB临床病理特征的关系及其临床意义。方法：应用免疫组织化学染色方法检测113例TCCB组织中Ki-67、p53及VEGF的表达，并将结果与临床分期、病理分级进行相关性分析。结果：TCCB中Ki-67、p53和VEGF的表达率分别为82.3%（93/113）、80.5%（91/113）、90.3%（102/113），Ki-67、p53的表达率及表达强度随着TCCB的临床分期、病理分级的升高而升高（P<0.05），VEGF的表达率和表达强度与肿瘤的临床分期呈正相关（P<0.05），与病理分级无显著相关性（P>0.05）；Ki-67与p53、VEGF均呈正相关，r分别为0.240、0.239，相关性有统计学意义（P<0.05）；在高分期、高分级组TCCB中Ki-67和p53、Ki-67和VEGF联合阳性表达率高于低分期、低分级组，差异有统计学意义（P<0.05）。结论：Ki-67的表达与TCCB的恶性程度有关，其与p53和VEGF的过度表达对TCCB的发生、发展起着协同的作用，Ki-67与p53、VEGF的联合检测更有助于TCCB临床分期、病理分级、预后判断及术后辅助治疗方案的制定。
- 膀胱肿瘤 /
- Ki-67抗原 /
- p53 /
- 血管内皮生长因子类
Abstract: Objective: To study the expression of Ki-67, p53 and VEGF in transitional cell carcinoma of the bladder (TCCB) tissue, and to investigate the relationship between the expression and clinicopathologic parameters in patients with TCCB.Method: The expression of Ki-67, p53 and VEGF in 113 cases of bladder cancer were assessed by immunohistochemistry, and their correlations with clinicopathological factors were statistically analyzed.Result: The expression rates of Ki-67, p53 and VEGF in bladder cancer were 82.3% (93/113), 80.5% (91/113), 90.3% (102/113) respectively. In addition, the expression rates and intensity of Ki-67 and p53 increased along with the rising of clinical stage and pathologic grade (P<0.05). The expression of VEGF is also positively correlated with clinical stage (P<0.05), but not with the pathologic grade (P>0.05). Ki-67 was positively correlated with p53 and VEGF, which were statistically significant (P<0.05). The positive co-expression rates of Ki-67, p53 in advanced-type and high-grade group were higher than that in the early-stage and low-grade group, which the same result could be seen in the positive co-expression rates of Ki-67 and VEGF. Thus, the difference was statistically significant (P<0.05).Conclusion: The expression of Ki-67 was associated with the degree of malignancy of bladder cancer. The over expression of Ki-67, p53 and VEGF might reveal synergistic action on the course of the occurrence, development of transitional cell carcinoma of the bladder. Detecting the expression of Ki-67 as well as p53 and VEGF can better indicate the clinical stage, pathologic grade, the prognosis and provide basis for postoperative adjunctive therapy.
- tumor of bladder /
- Ki-67 antigen /
- p53 /
- vascular endothelial growth factors

HTML全文

参考文献(11)

[1]	Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2]	Margulis V, Shariat S F, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease[J]. Clin Cancer Res, 2006, 12(24):7376-7373.
[3]	Onozawa M, Miyanaga N, Hinotsu S, et al. Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer[J]. Jpn J Clin Oncol, 2012, 42(9):825-830.
[4]	Kapur P, Lotan Y, King E, et al. Primary adenocarcinoma of the urinary bladder:value of cell cycle biomarkers[J]. Am J Clin Pathol, 2011, 135(6):822-830.
[5]	Margulis V, Lotan Y, Karakiewicz P I, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer[J]. J Natl Cancer Inst, 2009, 101(2):114-119.
[6]	Swana H S, Grossman D, Anthony J N, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer[J]. N Engl J Med, 1999, 341(6):452-453.
[7]	Schrier B P, Vriesema J L, Witjes J A, et al. The predictive value of p53, p27 (kip1), and alpha-catenin for progression in superficial bladder carcinoma[J]. Eur Urol, 2006, 50(1):76-82.
[8]	陈智彬,宋彦,宋永胜. 联合评估凋亡相关蛋白Survivin和突变型p53在膀胱移行细胞癌中的表达及意义[J]. 临床泌尿外科杂志, 2009, 24(1):35-37.
[9]	Piston E, Faynel J, Ruffion A, et al. p53 immunodetection of liquid-based processed urinary samples helps to indentify bladder tumors with a higher risk of progression[J]. Br J Cancer, 2005, 93(2):242-247.
[10]	杨立新,张海峰,白淑芬. p53、Ki-67基因表达与膀胱癌相关性的回顾性研究[J]. 现代医学, 2010, 38(1):32-35.
[11]	Hainsworth J D, Spigel D R, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site:the Minnie Pearl Cancer Research Network[J]. J Clin Oncol, 2007, 25(13):1747-1752.